// App-Quantinova.ai

275 : Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Daniel J. George

Principal Investigators

  • Susan Halabi

  • Patrick Healy

  • Sarah Gemberling

  • Carolyn Winters

  • Kelly Mundy

  • Michael Roger Harrison

  • Russell Zelig Szmulewitz

  • Andrew J. Armstrong

Medical Centers

  • Duke Cancer Institute, Durham, NC

  • Duke University Medical Center, Durham, NC

  • Duke University, Durham, NC

  • The University of Chicago Medical Center, Chicago, IL

  • Duke Cancer Institute, Duke University and the Department of Defense Prostate Cancer Clinical Trials Consortium, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Prednisone

  • Docetaxel

  • Pazopanib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01385228

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved